Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design

Pelin  Armutlu,  Muhuttin Emre Ozdemir,  Sule  Ozdas,  Ibrahim Halil Kavakli and   Metin  Turkay

Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design

Author(s): Pelin Armutlu, Muhuttin Emre Ozdemir, Sule Ozdas, Ibrahim Halil Kavakli, Metin Turkay

Affiliation:

Journal Name: Letters in Drug Design & Discovery

Volume 6 , Issue 5 , 2009

DOI : 10.2174/1570180810906050337

Journal Home

Abstract:

It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.

Keywords: Prostate Cancer, Androgen Biosynthesis, Cytochrome P450 enzyme 17R-hydroxylase-17, 20-lyase, Virtual Screening

Rights & Permissions Print Export Cite as

Letters in Drug Design & Discovery

Title: Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design

VOLUME: 6 ISSUE: 5

Author(s):Pelin Armutlu, Muhuttin Emre Ozdemir, Sule Ozdas, Ibrahim Halil Kavakli and Metin Turkay

Affiliation:Koc University, Colloge of Engineering, Rumeli Feneri Yolu Sariyer- Istanbul, Turkey.

Keywords:Prostate Cancer, Androgen Biosynthesis, Cytochrome P450 enzyme 17R-hydroxylase-17, 20-lyase, Virtual Screening

Abstract: It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Pelin Armutlu, Muhuttin Emre Ozdemir, Sule Ozdas, Ibrahim Halil Kavakli and Metin Turkay, “ Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design”, Letters in Drug Design & Discovery (2009) 6: 337. https://doi.org/10.2174/1570180810906050337

DOI https://doi.org/10.2174/1570180810906050337	Print ISSN 1570-1808
Publisher Name Bentham Science Publisher	Online ISSN 1875-628X

About this journal

Article Details

VOLUME: 6
ISSUE: 5
Year: 2009

Page: [337 - 344]
Pages: 8
DOI: 10.2174/1570180810906050337
Price: $65

Article Metrics

PDF: 8

Most Downloaded Article(s)

Meet Our Editorial Board Member
Letters in Drug Design & Discovery
A Screening Method for Potential Anti-pancreatic Cancer Candidate Compounds Based on Hsp90-Cdc37 Interaction Model in vitro
Letters in Drug Design & Discovery
Design, Synthesis and Evaluation of Novel 2-piperidinyl Quinoline Chalcones/ Amines as Potential Antidepressant Agents
Letters in Drug Design & Discovery
An Improved Preparation of (R)-3-Aminobutanol, a Key Intermediate for the Synthesis of Dolutegravir Sodium
Letters in Drug Design & Discovery
Novel Coronavirus (COVID-19) Outbreak: Hope and Search for Effective Therapeutic Agent
Letters in Drug Design & Discovery
Comparison in the Glucose Response of Flexible Liposomes Loaded with Insulin with the Addition of Different Surfactants in an Experimental Diabetes Model
Letters in Drug Design & Discovery
Structure-based Drug Design Strategies in the Development of Small Molecule Inhibitors Targeting Bcl-2 Family Proteins
Letters in Drug Design & Discovery
Synthesis of the Neurotransmitter 4-Aminobutanoic Acid (GABA) from Diethyl Cyanomalonate
Letters in Drug Design & Discovery
Lapatinib as a Dual Tyrosine Kinase Inhibitor Unexpectedly Activates Akt in MDA-MB-231 Triple-Negative Breast Cancer Cells
Letters in Drug Design & Discovery
Development of Phthalimide-Donepezil Hybrids as Potent Multitarget- Directed Ligands for the Treatment of Alzheimer’s Disease
Letters in Drug Design & Discovery